American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
WALTHAM, Mass., May 30, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017 at 11:00 a.m. Eastern Time.
The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
